News Quantified

ALLO – allogene therapeutics, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia

Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026

Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock

Allogene Therapeutics (ALLO) was upgraded by JPMorgan Chase & Co. from "underweight" to "neutral".

Allogene Therapeutics (ALLO) Is Down 13.0% After $175M Equity Raise On ALPHA3 MRD Data Release – Has The Bull Case Changed? [Yahoo! Finance]

-3.6%

BEAT

12.4%

BEAT

0.9%

BEAT

-16.4%

IN-LINE

JPMorgan Chase & Co.

Form 144 Allogene Therapeutics, Filed by: Yoshiyama Annie

Form PRE 14A Allogene Therapeutics, For: Apr 20

Form 8-K Allogene Therapeutics, For: Apr 14

Form 424B5 Allogene Therapeutics,

Form 424B5 Allogene Therapeutics,

Top News Gainers

2/6 Allogene Therapeutics Announces February and March 2020 Investor Conference Schedule 6.8%

3/18 Form 4 Allogene Therapeutics, For: Mar 16 Filed by: Chang David D 6.8%

3/17 Allogene Therapeutics Inc (NASDAQ: ALLO) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 6.7%

4/23 Form DEF 14A Allogene Therapeutics, For: Dec 31 5.9%

4/28 Form 4 Allogene Therapeutics, For: Apr 24 Filed by: Chang David D 5.9%

4/17 Allogene Therapeutics Inc (NASDAQ: ALLO) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 5.5%

8/7 Allogene Therapeutics, Inc. (ALLO) CEO David Chang on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] 5.0%

3/24 MaxCyte and Allogene Therapeutics Sign Clinical and Commercial License Agreement to Enable the Advancement of Allogeneic CAR T (AlloCAR T™) Therapies 4.9%

3/13 Allogene Therapeutics Inc (NASDAQ: ALLO) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $35.00 price target on the stock. 4.7%

2/24 Form 4 Allogene Therapeutics, For: Feb 20 Filed by: SCHMIDT ERIC THOMAS 4.4%

Top News Decliners

3/12 Allogene Therapeutics Inc (NASDAQ: ALLO) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -15.8%

11/6 Allogene Therapeutics Inc (NASDAQ: ALLO) had its "hold" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $29.00 price target on the stock. -6.4%

8/11 Allogene Therapeutics Inc (NASDAQ: ALLO) had its "hold" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $29.00 price target on the stock. -5.4%

8/12 Allogene Therapeutics Inc (NASDAQ: ALLO) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.2%

3/20 Senator Richard Burr Sold a Fortune in Stocks While Playing Down Coronavirus Threat [The New York Times] -5.1%

11/12 Allogene Moves Forward With CAR-T Therapy Pipeline [Seeking Alpha] -5.1%

4/1 Allogene Therapeutics Announces Participation in Two Upcoming Virtual Investor Conferences -4.9%

9/25 Form 4 Allogene Therapeutics, For: Sep 23 Filed by: Kazam Joshua A -4.8%

5/22 Allogene Therapeutics Inc (NASDAQ: ALLO) is now covered by analysts at Stifel Nicolaus. They set a "hold" rating on the stock. -4.8%

11/5 Q3/2019 9/30/2019 EPS -0.500 ZacksConsensus -0.540 ActVsEst 0.040 - Beat -4.4%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day